Acute candidiasis of vulva and vagina
ICD-10 B37.31 is a billable code used to indicate a diagnosis of acute candidiasis of vulva and vagina.
Acute candidiasis of the vulva and vagina, commonly known as a yeast infection, is a fungal infection caused primarily by the overgrowth of Candida species, particularly Candida albicans. This condition is characterized by inflammation, itching, and discomfort in the vulvar and vaginal areas. Patients may present with symptoms such as a thick, white vaginal discharge resembling cottage cheese, redness, and swelling of the vulva, and dysuria or pain during intercourse. Risk factors for acute candidiasis include antibiotic use, hormonal changes (such as those occurring during pregnancy or with oral contraceptives), uncontrolled diabetes, and immunocompromised states. In immunocompromised patients, such as those with HIV/AIDS or undergoing chemotherapy, the risk of recurrent and severe candidiasis increases significantly. Treatment typically involves antifungal medications, which can be administered topically or orally, depending on the severity of the infection. It is crucial for healthcare providers to accurately diagnose and code this condition to ensure appropriate treatment and management.
Detailed patient history, including symptoms, risk factors, and treatment response.
Patients presenting with recurrent yeast infections, pregnant patients, and those with diabetes.
Consideration of hormonal influences and potential complications in pregnant patients.
Comprehensive assessment of immunocompromised status and history of candidiasis.
Patients with HIV/AIDS or those undergoing immunosuppressive therapy.
Need for thorough evaluation of systemic candidiasis in severely immunocompromised patients.
Used when a fungal culture is needed to confirm candidiasis.
Document the reason for culture and any previous treatments.
Important for infectious disease specialists to confirm diagnosis.
Common symptoms include itching, burning, and a thick, white discharge resembling cottage cheese. Patients may also experience redness and swelling of the vulva.
Treatment typically involves antifungal medications, which can be administered topically or orally, depending on the severity of the infection.
Risk factors include antibiotic use, hormonal changes, uncontrolled diabetes, and immunocompromised states.
